

Redx Pharma Plc

07:43 10 Jun 2019

Redx Pharma secures short-term funding; assessing longer-term solutions

Redx Pharma (LON:REDX) has secured short-term funding with a loan of up to £2.5m and is in talks to find a longer-term financing solution.

Shareholder Moulton Goodies Ltd has agreed to provide the secured loan note facility, with £1m being drawn down immediately. The coupon is 10% a year and there is an option to turn the debt into equity in certain circumstances.

At the same time boss Lisa Anson and her executive team remain in "active discussions" with shareholders and "third-party healthcare specialist investors" to find a more sustainable and efficient method of bankrolling the group.

Value realisation

Investors were told Redx is also looking to "pursue potential value realisation opportunities" for its pan-RAF cancer research programme.

"The company will provide further updates in due course," the firm added.

The loan runs until the end of the year and can be capitalised in the event of an equity fundraiser of at least £10m (though there are provisions to turn the debt into shares at a lesser amount). Moulton, which owns 18.6% of Redx, would receive new shares at a discount to the price they are offered.

As the lender owns such a large chunk of the business it is being treated as what's called a related-party transaction under AIM's rules. Therefore, Redx took advice before agreeing the financing deal.

"The board consider that the terms of the loan are fair and reasonable insofar as the company's shareholders are concerned, having consulted with Cantor Fitzgerald Europe, the company's nominated adviser," shareholders were told.

Results update

In a separate update, Redx published financial results for the six months to the end of March, which showed the company had £3.3m in the bank at that point, although operating expenses for the period were £5m.

Initial results from a phase I study of its lead drug, RXC004, a porcupine inhibitor aimed at treating cancer driven by the Wnt pathway, are expected in the second half of the year, with the full read-out expected in early 2020.


Currently one patient has received a first cycle of treatment with two joining the first group soon. Redx believes the "required exposures" to the drug will be in the 0.5-3mg range.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

Price: 7

Market Cap: £8.85 m

1 Year Share Price Graph



November 2018 May 2019 November 20

Share Information

Code: REDX

Listing: AIM

52 week	High	Low
	14.8375	4.75

Sector: Pharma & Biotech

Website: www.redxpharma.com

Company Synopsis:

Focused on the development of novel medicines to validated anti-cancer and fibrosis targets in areas of unmet need

Redx Pharma uses its proven drug discovery expertise to generate development candidates that it will take into the clinic and then partner.

action@proactiveinvestors.com

investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).